Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1695 clinical trials
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor activity of TTX-080 as monotherapy in adults with unresectable or metastatic solid tumors known to express HLA-G.

metastasis
solid tumour
measurable disease
hla-g
cancer
  • 0 views
  • 05 Aug, 2020
Titration of Oxygen Levels During Mechanical Ventilation With Electronic Alerts

Fractional oxygen during mechanical ventilation, is a life sustaining therapy in the intensive care unit , used for about a million patients annually. Oxygen therapy needs to be tightly balanced as both hypoxia and hyperoxia are harmful. Establishing precision in oxygenation has significant implications for improving patient outcomes, resource utilization …

hypoxia
hyperoxia
alert
mechanical ventilation
critical illness
  • 0 views
  • 05 Aug, 2020
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy (SABR) plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer. The patients will receive standard SABR + nivolumab at a dose of 360 mg every 21 days for …

gilbert's syndrome
neoadjuvant treatment
forced expiratory volume
bilateral oophorectomy
non-small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to the pre baseline measurement.

leukopenia
pneumonia
covid-19
respiratory complications
neutropenia
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Provider Burnout During COVID-19

Annals of Internal Medicine 2019). While burnout has been described as a reaction to chronic work-related stress (Melamed et al. Psychol. Bull. 2006), individual factors such as anxiety increase susceptibility to burnout (Sun et al.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Study to Assess AFM24 in Advanced Solid Cancers

AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

cancer treatment
kidney cancer
small cell lung cancer
lung cancer
colorectal cancer
  • 0 views
  • 16 Feb, 2024
  • 4 locations
Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis

Actinic cheilitis is a potentially malignant lesion on the lower lip, which can progress to more serious illnesses such as cancer if not treated. Usually treatment of this condition is only based on clinical appearance, but there is no established cure treatment.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
PHP and Immunotherapy in Metastasized UM

With this treatment combination we aim to find a treatment for disseminated uveal melanoma, both in the liver as in the other organs.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. This study will be used to define the recommended Phase 2 dose (RP2D).

solid neoplasm
measurable disease
ejection fraction
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Safety Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects. There are 6 Groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 …

  • 0 views
  • 16 Feb, 2024
  • 1 location